4.7 Article

The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study

期刊

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 39, 期 8, 页码 802-810

出版社

WILEY
DOI: 10.1111/apt.12669

关键词

-

资金

  1. Olympus America
  2. Bankhead-Coley Team Science Program
  3. Sylvester Comprehensive Cancer Center of University of Miami
  4. American Cancer Society

向作者/读者索取更多资源

Background Studies have found that depression is more frequent in patients with inflammatory bowel disease (IBD) than the general population. Clinicians are now trying to pinpoint risk factors for psychological impairment in the IBD population. Aims To examine the demographic and phenotypic variables associated with the development of depression among a diverse cohort of IBD patients. We also sought to describe psychotropic therapy prescribed to IBD patients. Methods We conducted a retrospective cohort study including patients with Crohn's disease (CD) and ulcerative colitis (UC) without a prior psychiatric diagnosis and followed in the gastroenterology clinics of the private university hospital and public safety net hospital at a large academic centre in Miami (Florida). Predictive variables included demographic characteristics, IBD phenotype, exposure to IBD medications, history of a surgical stoma or seton placement, extra-intestinal manifestations, laboratory indices, aggressive disease and disease activity (based on imaging and endoscopic parameters). Proportional hazard regression models and stepwise Cox regression analysis were used for statistical analysis. Results Independent predictors of depression were female gender [HR: 1.3 (95% CI: 1.1-1.7), P=0.01], aggressive disease [HR: 1.4 (95% CI: 1.02-1.9), P=0.03] and active disease [HR: 1.5 (95% CI: 1.1-2.0), P=0.04]. In the group that did develop a depressive disorder, 65% received pharmacologic therapy with one or more psychotropic agents. Conclusions We found female gender, aggressive disease and increased endoscopic/radiological activity to be independently associated with the development of depression in inflammatory bowel disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction

Shiran Gerassy-Vainberg, Alexandra Blatt, Yael Danin-Poleg, Katya Gershovich, Edmond Sabo, Alex Nevelsky, Shahar Daniel, Aviva Dahan, Oren Ziv, Rishu Dheer, Maria T. Abreu, Omry Koren, Yechezkel Kashi, Yehuda Chowers

Article Gastroenterology & Hepatology

Hispanics Coming to the US Adopt US Cultural Behaviors and Eat Less Healthy: Implications for Development of Inflammatory Bowel Disease

Oriana M. Damas, Derek Estes, Danny Avalos, Maria A. Quintero, Diana Morillo, Francia Caraballo, Johanna Lopez, Amar R. Deshpande, David Kerman, Jacob L. McCauley, Ana Palacio, Maria T. Abreu, Seth J. Schwartz

DIGESTIVE DISEASES AND SCIENCES (2018)

Article Gastroenterology & Hepatology

Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy

Andres J. Yarur, Anjali Jain, Maria A. Quintero, Frank Czul, Amar R. Deshpande, David H. Kerman, Maria T. Abreu

JOURNAL OF CLINICAL GASTROENTEROLOGY (2019)

Article Immunology

Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines

Jason Miska, Jen Bon Lui, Kevin H. Toomer, Priyadharshini Devarajan, Xiaodong Cai, JeanMarie Houghton, Diana M. Lopez, Maria T. Abreu, Gaofeng Wang, Zhibin Chen

JOURNAL OF EXPERIMENTAL MEDICINE (2018)

Article Multidisciplinary Sciences

Fluid supplementation accelerates epithelial repair during chemical colitis

Juan F. Burgueno, Jessica K. Lang, Ana M. Santander, Irina Fernandez, Ester Fernandez, Julia Zaias, Maria T. Abreu

PLOS ONE (2019)

Article Multidisciplinary Sciences

Morphine tolerance is attenuated in germfree mice and reversed by probiotics, implicating the role of gut microbiome

Li Zhang, Jingjing Meng, Yuguang Ban, Richa Jalodia, Irina Chupikova, Irina Fernandez, Nivis Brito, Umakant Sharma, Maria T. Abreu, Sundaram Ramakrishnan, Sabita Roy

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Article Medicine, General & Internal

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

B. E. Sands, W. J. Sandborn, R. Panaccione, C. D. O'Brien, H. Zhang, J. Johanns, O. J. Adedokun, K. Li, L. Peyrin-Biroulet, G. Van Assche, S. Danese, S. Targan, M. T. Abreu, T. Hisamatsu, P. Szapary, C. Marano

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Editorial Material Gastroenterology & Hepatology

DDS Profile: Maria T. Abreu, MD

Maria T. Abreu

DIGESTIVE DISEASES AND SCIENCES (2019)

Editorial Material Gastroenterology & Hepatology

DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD

Maria T. Abreu

DIGESTIVE DISEASES AND SCIENCES (2019)

Editorial Material Gastroenterology & Hepatology

Exposing the Achilles Heel of Antibiotic Therapy for Pouchitis Using Microbial Function and Composition

Julia Fritsch, Maria T. Abreu

GASTROENTEROLOGY (2020)

Review Gastroenterology & Hepatology

Epithelial Toll-like receptors and their role in gut homeostasis and disease

Juan F. Burgueno, Maria T. Abreu

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Editorial Material Gastroenterology & Hepatology

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

Maria T. Abreu, William J. Sandborn

GASTROENTEROLOGY (2020)

Editorial Material Gastroenterology & Hepatology

Challenges and Opportunities in IBD Clinical Trial Design

Marla C. Dubinsky, Rory Collins, Maria T. Abreu

GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy

Maria T. Abreu, Julie M. Davies, Maria A. Quintero, Amber Delmas, Sophia Diaz, Catherine D. Martinez, Thomas Venables, Adrian Reich, Gogce Crynen, Amar R. Deshpande, David H. Kerman, Oriana M. Damas, Irina Fernandez, Ana M. Santander, Judith Pignac-Kobinger, Juan F. Burgueno, Mark S. Sundrud

Summary: Vedolizumab (VDZ) is effective in the treatment of inflammatory bowel disease (IBD) by inhibiting lymphocyte extravasation into intestinal mucosae. Changes in T regulatory cells in the periphery and mucosa have the greatest relationship to VDZ response.

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

Reclassifying Pseudopolyps in Inflammatory Bowel Disease: Histologic and Endoscopic Description in the New Era of Mucosal Healing

Mona Rezapour, Maria Alejandra Quintero, Nidah S. Khakoo, Daniel A. Sussman, Jodie A. Barkin, Jennifer Clarke, Tanya Varma, Amar R. Deshpande, David H. Kerman, Oriana Damas, Maria T. Abreu

CROHNS & COLITIS 360 (2019)

暂无数据